Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Cash from Investing Activities (2018 - 2025)

Historic Cash from Investing Activities for Vistagen Therapeutics (VTGN) over the last 11 years, with Q4 2025 value amounting to $104000.0.

  • Vistagen Therapeutics' Cash from Investing Activities rose 12464.45% to $104000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$251000.0, marking a year-over-year increase of 9816.84%. This contributed to the annual value of -$13.1 million for FY2025, which is 2145409.84% down from last year.
  • Latest data reveals that Vistagen Therapeutics reported Cash from Investing Activities of $104000.0 as of Q4 2025, which was up 12464.45% from -$94000.0 recorded in Q3 2025.
  • In the past 5 years, Vistagen Therapeutics' Cash from Investing Activities registered a high of $527000.0 during Q1 2025, and its lowest value of -$7.8 million during Q3 2024.
  • Its 5-year average for Cash from Investing Activities is -$839044.4, with a median of -$63000.0 in 2023.
  • Per our database at Business Quant, Vistagen Therapeutics' Cash from Investing Activities plummeted by 52790000.0% in 2023 and then surged by 191724.14% in 2025.
  • Over the past 5 years, Vistagen Therapeutics' Cash from Investing Activities (Quarter) stood at $100.0 in 2021, then tumbled by 12600.0% to -$12500.0 in 2022, then plummeted by 156.0% to -$32000.0 in 2023, then tumbled by 1218.75% to -$422000.0 in 2024, then skyrocketed by 124.64% to $104000.0 in 2025.
  • Its Cash from Investing Activities was $104000.0 in Q4 2025, compared to -$94000.0 in Q3 2025 and -$788000.0 in Q2 2025.